A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group.

Molecular cloning of a cDNA encoding human antihaemophilic factor

1984 • 937 citations

Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs

1992 • 613 citations

Applied Statistics: Analysis of Variance and Regression.

1976 • 608 citations

[Changes under the influence of high pressure of certain properties of myosin, actomyosin and actin].

1960 • 499 citations

A More Uniform Measurement of Factor VIII Inhibitors

1975 • 498 citations

Stabilization of Factor VIII in Plasma by the von Willebrand Factor

1977 • 421 citations

Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells.

1988 • 385 citations

Human Recombinant DNA–Derived Antihemophilic Factor (Factor VIII) in the Treatment of Hemophilia A

1990 • 261 citations

Non-A non-B hepatitis after transfusion of factor VIII in infrequently treated patients.

1983 • 219 citations

A Higher than Expected Incidence of Factor VIII Inhibitors in Multitransfused Haemophilia A Patients Treated with an Intermediate Purity Pasteurized Factor VIII Concentrate

1993 • 189 citations

Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease

1982 • 180 citations

A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group

1993 • 179 citations

Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells.

1989 • 178 citations

A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group

1993 • 172 citations

The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors

1988 • 171 citations

Human parvovirus B19 infection in hemophiliacs first infused with two high‐purity, virally attenuated factor Vlll concentrates

1992 • 171 citations

Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII

1993 • 164 citations

Use of Recombinant Antihemophilic Factor in the Treatment of Two Patients with Classic Hemophilia

1989 • 162 citations

Absence of Hepatitis after Treatment with a Pasteurized Factor VIII Concentrate in Patients with Hemophilia and No Previous Transfusions

1987 • 160 citations

High risk of non‐A non‐B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effects of prophylactic immune serum globulin

1985 • 153 citations

Purification of human factor VIII:C and its characterization by Western blotting using monoclonal antibodies

1985 • 142 citations

Isolation and characterization of human factor VIII: molecular forms in commercial factor VIII concentrate, cryoprecipitate, and plasma.

1986 • 140 citations

VIRUS SAFETY OF SOLVENT/DETERGENT-TREATED ANTIHAEMOPHILIC FACTOR CONCENTRATE

1988 • 137 citations

Survival of 125iodine-labeled Factor VIII in normals and patients with classic hemophilia. Observations on the heterogeneity of human Factor VIII.

1978 • 99 citations

Incidence of inhibitors in patients with severe and moderate hemophilia a treated with factor VIII concentrates

1987 • 77 citations

Absence of Anti-Human Immunodeficiency Virus Types 1 and 2 Seroconversion after the Treatment of Hemophilia A or von Willebrand's Disease with Pasteurized Factor VIII Concentrate

1989 • 74 citations

A two-phase linear regression model for biologic half-life data.

1990 • 64 citations

Human factor VIII procoagulant protein. Monoclonal antibodies define precursor-product relationships and functional epitopes.

1985 • 61 citations

Treatment of Hemophilia with Glycine-Precipitated Factor VIII

1966 • 60 citations

Pharmacokinetic Properties of Recombinant Factor VIII Compared with a Monoclonally Purified Concentrate (Hemofil® M)

1992 • 42 citations

Acute Hepatitis Non-A, Non-B following Administration of Factor VIII Concentrates

1981 • 32 citations

Antihemophilic globulin assay following plasma infusions in hemophilia.

1958 • 25 citations

Experimental Prophylaxis of Severe Hemophilia With a Factor VIII Concentrate

1969 • 24 citations

Hepatitis transmission by blood products

1988 • 4 citations